Ann: Voluntary Suspension Extension Request, page-66

http://www.*.com/companies/news/197...-two-canadian-patent-applications-197738.html

Canntab Therapeutics Ltd (CSEILL) announced today that it recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.
The company, which offers medical marijuana in pill form, said the new applications were related to oral formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and sustained release cannabinoid pellets. Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.
READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product

The new patent applications extend Canntab’s intellectual property portfolio, which includes patent applications and trademark applications in the United States and Canada.
Canntab is currently developing a number of products, which include an extended-release tablet that contains a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that may be helpful in the treatment of a number of ailments.
These include: sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers.
WATCH: Canntab Therapeutics debuts shares on 'serendipitous' 4/20

Most conventional dosing forms release the active drug immediately after taking it orally. In sustained release forms, the active ingredient is released at a steady rate, which maintains a constant concentration over a time period. Canntab’s product is designed to release the cannaboid content over a period of at least 12 hours.
The company is currently in the process of seeking approval from Health Canada on its extended release tablets and is making batches of the tablets for third-party clinical trials in Canada. Canntab also plans to enter the US market by obtaining a manufacturing and distributors license in certain US states.
Shares were up 1.11% at C$0.91 on Friday.